| FDA-approved drugs for the most common type of hair loss, androgenetic alopecia
(AGA), present many side effects and disadvantages. However, herbal compounds
are characterized by patient compliance, fewer side effects, and several mechanisms
of action. The present study set to evaluate the effectiveness and safety of the
topical herbal solution and to compare it with 5% minoxidil in men with AGA. A randomized,
double-blind controlled trial was conducted from 28 November 2018 to
2 September 2019, in Sina Hospital, Tabriz, Iran. 24 healthy males (mean [SD] age
33.04 [5.81]) with mild to moderate AGA were selected from 44 volunteer participants.
Participants were randomly assigned (1:1) into two groups. They received 1 ml
of topical solutions at morning and evening intervals for 9 months. Primary outcomes
consisted of measured hair diameters at baseline and repeated at weeks 12, 24,
and 36. Furthermore, hair density was measured at baseline and week 36. The
MTS + THS group was significantly superior to the MTS group after 36 weeks of
therapy in the hair diameter improvement. At week 36, the mean hair diameter of
the MTS + THS group significantly increased compared to the MTS group (P = .001).
Hair density increased in both groups; however, only in the MTS + THS group, it was
significant (P < .05). The findings established that the topical herbal solution has significant
influence on patients with AGA and improvement of their quality of life. This
solution can be considered a significant step towards the prevention and treatment
of AGA. clinicaltrials.gov Identifier |